Pharmaceutical Research

, Volume 32, Issue 9, pp 3055–3065 | Cite as

Developing Enhanced Blood–Brain Barrier Permeability Models: Integrating External Bio-Assay Data in QSAR Modeling

  • Wenyi Wang
  • Marlene T. Kim
  • Alexander Sedykh
  • Hao Zhu
Research Paper



Experimental Blood–Brain Barrier (BBB) permeability models for drug molecules are expensive and time-consuming. As alternative methods, several traditional Quantitative Structure-Activity Relationship (QSAR) models have been developed previously. In this study, we aimed to improve the predictivity of traditional QSAR BBB permeability models by employing relevant public bio-assay data in the modeling process.


We compiled a BBB permeability database consisting of 439 unique compounds from various resources. The database was split into a modeling set of 341 compounds and a validation set of 98 compounds. Consensus QSAR modeling workflow was employed on the modeling set to develop various QSAR models. A five-fold cross-validation approach was used to validate the developed models, and the resulting models were used to predict the external validation set compounds. Furthermore, we used previously published membrane transporter models to generate relevant transporter profiles for target compounds. The transporter profiles were used as additional biological descriptors to develop hybrid QSAR BBB models.


The consensus QSAR models have R2 = 0.638 for five-fold cross-validation and R2 = 0.504 for external validation. The consensus model developed by pooling chemical and transporter descriptors showed better predictivity (R2 = 0.646 for five-fold cross-validation and R2 = 0.526 for external validation). Moreover, several external bio-assays that correlate with BBB permeability were identified using our automatic profiling tool.


The BBB permeability models developed in this study can be useful for early evaluation of new compounds (e.g., new drug candidates). The combination of chemical and biological descriptors shows a promising direction to improve the current traditional QSAR models.


biological descriptors blood–brain barrier hybrid model permeability 





Applicability domain


Absorption, distribution, metabolism, and excretion


PubChem bio-assay identifier


Aldehyde dehydrogenase 1 family, member A1


Androgen receptor


Apical sodium-dependent bile acid transporter


Blood–brain barrier


Bile salt export pump


Cyclic adenosine monophosphate


PubChem compound identifier


Central nervous system


Estrogen receptor alpha


Human intestinal transporters


High throughput screening


k-nearest neighbor


Logarithm of brain-plasma concentration ratio at steady-state


Mean absolute error


Monocarboxylic acid transporters


Multidrug resistance


Multidrug resistance protein 1


Molecular operating environment software


Multidrug resistance-associated protein 1


Multidrug resistance-associated protein 3


Multidrug resistance-associated protein 4


Multidrug resistance-associated protein 5


Organic anion transporting polypeptides


Principle component analysis


Quantitative structure-activity relationship


Random forest


Support vector machine



Research reported in this publication was supported, in part, by the National Institute of Environmental Health Sciences of the National Institutes of Health under Award Number R15ES023148 and the Colgate-Palmolive Grant for Alternative Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Supplementary material

11095_2015_1687_MOESM1_ESM.docx (1.6 mb)
Figure S1 (DOCX 1647 kb)
11095_2015_1687_MOESM2_ESM.xlsx (12 kb)
Table SI (XLSX 11 kb)
11095_2015_1687_MOESM3_ESM.xlsx (30 kb)
Table SII (XLSX 30 kb)
11095_2015_1687_MOESM4_ESM.xlsx (25 kb)
Table SIII (XLSX 24 kb)


  1. 1.
    Abbott NJ. Blood–brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36(3):437–49.PubMedCrossRefGoogle Scholar
  2. 2.
    Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. Drug metabolism and pharmacokinetics, the blood–brain barrier, and central nervous system drug discovery. NeuroRx. 2005;2(4):554–71.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Andersen HR, Nielsen JB, Grandjean P. Toxicologic evidence of developmental neurotoxicity of environmental chemicals. Toxicology. 2000;144(1–3):121–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Maggiora GM. On outliers and activity cliffs–why QSAR often disappoints. J Chem Inf Model Am Chem Soc. 2006;46(4):1535.CrossRefGoogle Scholar
  5. 5.
    Bajorath J, Peltason L, Wawer M, Guha R, Lajiness MS, Van Drie JH. Navigating structure-activity landscapes. Drug Discov Today. 2009;14(13–14):698–705.PubMedCrossRefGoogle Scholar
  6. 6.
    Zhu H, Zhang J, Kim MT, Boison A, Sedykh A, Moran K. Big data in chemical toxicity research: the use of high-throughput screening assays to identify potential toxicants. Chem Res Toxicol Am Chem Soc. 2014;27(10):1643–51.CrossRefGoogle Scholar
  7. 7.
    Joó F, Rakonczay Z, Wollemann M. cAMP-Mediated regulation of the permeability in the brain capillaries. Experientia. 1975;31(5):582–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Sedykh A, Fourches D, Duan J, Hucke O, Garneau M, Zhu H, et al. Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013;30(4):996–1007.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Zhang J, Hsieh J-H, Zhu H. Profiling animal toxicants by automatically mining public bioassay data: a big data approach for computational toxicology. Homayouni R, editor. PLoS One Public Libr Sci. 2014 Jan;9(6):e99863.Google Scholar
  10. 10.
    Muehlbacher M, Spitzer GM, Liedl KR, Kornhuber J. Qualitative prediction of blood–brain barrier permeability on a large and refined dataset. J Comput Aided Mol Des. 2011;25(12):1095–106.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Vilar S, Chakrabarti M, Costanzi S. Prediction of passive blood–brain partitioning: straightforward and effective classification models based on in silico derived physicochemical descriptors. J Mol Graph Model. 2010;28(8):899–903.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Hou TJ, Xu XJ. ADME evaluation in drug discovery. 3. Modeling blood–brain barrier partitioning using simple molecular descriptors. J Chem Inf Comput Sci. 2003;43(6):2137–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Abraham MH, Ibrahim A, Zhao Y, Acree WE. A data base for partition of volatile organic compounds and drugs from blood/plasma/serum to brain, and an LFER analysis of the data. J Pharm Sci. 2006;95(10):2091–100.PubMedCrossRefGoogle Scholar
  14. 14.
    Mensch J, Jaroskova L, Sanderson W, Melis A, Mackie C, Verreck G, et al. Application of PAMPA-models to predict BBB permeability including efflux ratio, plasma protein binding and physicochemical parameters. Int J Pharm. 2010;395(1–2):182–97.PubMedCrossRefGoogle Scholar
  15. 15.
    Ooms F, Weber P, Carrupt P-A, Testa B. A simple model to predict blood–brain barrier permeation from 3D molecular fields. Biochim Biophys Acta Mol Basis Dis. 2002;1587(2–3):118–25.CrossRefGoogle Scholar
  16. 16.
    Breiman L. Random forests. Mach Learn. Kluwer Academic Publishers; 2001 Oct 1;45(1):5–32.Google Scholar
  17. 17.
    Vapnik V. The nature of statistical learning theory. Springer Science & Business Media; 2000.Google Scholar
  18. 18.
    Dalgaard P. Introductory Statistics with R. Springer Science & Business Media; 2008.Google Scholar
  19. 19.
    Zheng W, Tropsha A. Novel variable selection quantitative structure–property relationship approach based on the k-nearest-neighbor principle. J Chem Inf Model Am Chem Soc. 2000;40(1):185–94.CrossRefGoogle Scholar
  20. 20.
    Walker T, Grulke CM, Pozefsky D, Tropsha A. Chembench: a cheminformatics workbench. Bioinformatics. 2010;26(23):3000–1.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Solimeo R, Zhang J, Kim M, Sedykh A, Zhu H. Predicting chemical ocular toxicity using a combinatorial QSAR approach. Chem Res Toxicol Am Chem Soc. 2012;25(12):2763–9.CrossRefGoogle Scholar
  22. 22.
    Zhang L, Zhu H, Oprea TI, Golbraikh A, Tropsha A. QSAR modeling of the blood–brain barrier permeability for diverse organic compounds. Pharm Res. 2008;25(8):1902–14.PubMedCrossRefGoogle Scholar
  23. 23.
    Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H. Critical evaluation of human oral bioavailability for pharmaceutical drugs by using various cheminformatics approaches. Pharm Res. 2014;31(4):1002–14.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Tropsha A, Golbraikh A. Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Curr Pharm Des. Bentham Science Publishers; 2007 Dec 1;13(34):3494–504.Google Scholar
  25. 25.
    Golbraikh A, Shen M, Xiao Z, Xiao Y-D, Lee K-H, Tropsha A. Rational selection of training and test sets for the development of validated QSAR models. J Comput Aided Mol Des. Kluwer Academic Publishers; 2003 Feb 1;17(2–4):241–53.Google Scholar
  26. 26.
    Walters HC, Craddock AL, Fusegawa H, Willingham MC, Dawson PA. Expression, transport properties, and chromosomal location of organic anion transporter subtype 3. Am J Physiol Gastrointest Liver Physiol. 2000;279(6):G1188–200.PubMedGoogle Scholar
  27. 27.
    Hagenbuch B, Dawson P. The sodium bile salt cotransport family SLC10. Pflugers Arch. 2004;447(5):566–70.PubMedCrossRefGoogle Scholar
  28. 28.
    Kusuhara H, Sugiyama Y. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release. 2002;78(1–3):43–54.PubMedCrossRefGoogle Scholar
  29. 29.
    Gerloff T. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem. 1998;273(16):10046–50.PubMedCrossRefGoogle Scholar
  30. 30.
    Tsuji A, Tamai I. Carrier-mediated or specialized transport of drugs across the blood–brain barrier. Adv Drug Deliv Rev. 1999;36(2–3):277–90.PubMedCrossRefGoogle Scholar
  31. 31.
    Demeule M, Shedid D, Beaulieu E, Del Maestro RF, Moghrabi A, Ghosn PB, et al. Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int J Cancer. 2001;93(1):62–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Huai-Yun H, Secrest DT, Mark KS, Carney D, Brandquist C, Elmquist WF, et al. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells. Biochem Biophys Res Commun. 1998;243(3):816–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Roberts LM, Black DS, Raman C, Woodford K, Zhou M, Haggerty JE, et al. Subcellular localization of transporters along the rat blood–brain barrier and blood-cerebral-spinal fluid barrier by in vivo biotinylation. Neuroscience. 2008;155(2):423–38.PubMedCrossRefGoogle Scholar
  34. 34.
    Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DKF, Asperen J, et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdrla P-glycoprotein. Br J Pharmacol. 1996;119(5):1038–44.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Zhu H, Martin TM, Ye L, Sedykh A, Young DM, Tropsha A. Quantitative structure-activity relationship modeling of rat acute toxicity by oral exposure. Chem Res Toxicol Am Chem Soc. 2009;22(12):1913–21.CrossRefGoogle Scholar
  36. 36.
    Zhu H, Tropsha A, Fourches D, Varnek A, Papa E, Gramatica P, et al. Combinatorial QSAR modeling of chemical toxicants tested against Tetrahymena pyriformis. J Chem Inf Model. 2008;48(4):766–84.PubMedCrossRefGoogle Scholar
  37. 37.
    Sedykh A, Zhu H, Tang H, Zhang L, Richard A, Rusyn I, et al. Use of in vitro HTS-derived concentration-response data as biological descriptors improves the accuracy of QSAR models of in vivo toxicity. Environ Health Perspect. 2011;119(3):364–70.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Zhu H, Rusyn I, Richard A, Tropsha A. Use of cell viability assay data improves the prediction accuracy of conventional quantitative structure-activity relationship models of animal carcinogenicity. Environ Health Perspect. 2008;116(4):506–13.PubMedCentralPubMedGoogle Scholar
  39. 39.
    Hammarlund-Udenaes M, Fridén M, Syvänen S, Gupta A. On the rate and extent of drug delivery to the brain. Pharm Res. 2008;25(8):1737–50.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Ohtsuki S, Tomi M, Hata T, Nagai Y, Hori S, Mori S, et al. Dominant expression of androgen receptors and their functional regulation of organic anion transporter 3 in rat brain capillary endothelial cells; comparison of gene expression between the blood–brain and -retinal barriers. J Cell Physiol. 2005;204(3):896–900.PubMedCrossRefGoogle Scholar
  41. 41.
    Sharma HS, Dey PK. Impairment of blood–brain barrier (BBB) in rat by immobilization stress: role of serotonin (5-HT). Indian J Physiol Pharmacol. 1981;25(2):111–22.PubMedGoogle Scholar
  42. 42.
    Banks W, Kastin A, Komaki G, Arimura A. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood- brain barrier. J Pharmacol Exp Ther. 1993;267(2):690–6.PubMedGoogle Scholar
  43. 43.
    Cai C, Omwancha J, Hsieh C-L, Shemshedini L. Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells. Prostate Cancer Prostatic Dis. 2007;10(1):39–45.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Wenyi Wang
    • 1
  • Marlene T. Kim
    • 1
    • 2
  • Alexander Sedykh
    • 2
    • 3
  • Hao Zhu
    • 1
    • 2
  1. 1.The Rutgers Center for Computational and Integrative BiologyCamdenUSA
  2. 2.Department of ChemistryRutgers UniversityCamdenUSA
  3. 3.Multicase Inc.BeachwoodUSA

Personalised recommendations